Format

Send to:

Choose Destination
See comment in PubMed Commons below
Rev Recent Clin Trials. 2010 Jan;5(1):57-62.

The pulse of drug development for Alzheimer's disease.

Author information

  • 1Alzheimer's Disease Cooperative Study, Attending Neurologist, Shiley-Marcos Alzheimer's Disease Research Center, University of California, San Diego, USA. mrafii@ucsd.edu

Abstract

Therapies that are believed to target the underlying mechanisms of Alzheimer's disease have now reached human clinical trials, with the number of agents in late stage development having increased dramatically in recent years. Primary targets include beta-amyloid, whose presence and accumulation in the brain is thought to contribute to the development of Alzheimer's disease, and tau protein which, when hyperphosphorylated, results in the formation of neurofibrillary tangles of paired helical filaments, also believed to be involved in the pathogenesis of Alzheimer's disease. In this review, the current status of Alzheimer's Disease therapies under study is discussed, including the scientific basis for each strategy.

PMID:
20205688
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Bentham Science Publishers Ltd.
    Loading ...
    Write to the Help Desk